期刊文献+

氟康唑在隐球菌脑膜炎治疗中的应用探讨

Application of fluconazole in treatment of cryptococcal meningitis
下载PDF
导出
摘要 目的研究氟康唑在隐球菌脑膜炎治疗中的应用效果。方法我院2012年4月~2014年11月收治的40例隐球菌脑膜炎患者。按照简单随机化法将40例患者分为对照组和试验组。对照组以两性酶素B联合氟康唑治疗,试验组以单用氟康唑治疗。观察总有效率、不良反应发生率、治疗前和治疗后患者电解质钾、氯、钙和钠水平的差异,以及脑脊液隐球菌菌数降低情况。结果 (1)试验组和对照组总有效率相似,差异无统计学意义(P〉0.05);(2)试验组比对照组不良反应发生率更低,差异有统计学意义(P〈0.05);(3)治疗前两组电解质钾、氯、钙和钠水平相似,差异无统计学意义(P〉0.05);治疗后两组血钾明显降低,血氯、血钠明显升高,差异有统计学意义(P〈0.05)。而血钙则跟治疗前无明显变化,差异无统计学意义(P〉0.05)。(4)试验组相对照组脑脊液隐球菌菌数降低更显著,差异有统计学意义(P〈0.05)。结论单用氟康唑在隐球菌脑膜炎治疗中的应用效果确切,可有效降低脑脊液隐球菌菌数,但需要加强副作用的监测,做到合理、安全用药。 Objective To investigate the application effect of fluconazole in treatment of cryptococcal meningitis.Methods 40 patients with cryptococcal meningitis treated in our hospital from April 2012 to November 2014. Grouping method: Simple randomization. The 40 patients were divided into control group and study group. Patients in the control group were treated by amphotericin B combined with fluconazole, while patients in the study group were treated by single fluconazole. The overall response rate,incidence rate of adverse reaction,differences in electrolyte levels of potassium, chlorine, calcium, and sodium,reduction of microbial content of cerebrospinal fluid Cryptococcus were observed and compared. Results(1)The overall response rates in the study group and the control group were similar, without significant difference(P〉0.05);(2)The incidence rate of adverse event was significantly lower in the study group than in the control group(P〈0.05);(3)The electrolyte levels of potassium, chlorine, calcium, and sodium were similar between two groups before treatment, without significant difference(P〉0.05); while after treatment, the level of potassium significantly increased and levels of chlorine and sodium significantly reduced in both groups, which was significantly different(P〈0.05). There was no significant difference in level of calcium before and after treatment(P〉0.05).(4)The reduction of microbial content of cerebrospinal fluid cryptococcus was more significant in the study group than in the control group(P〈0.05). Conclusion Single use of fluconazole has definite effect in treatment of cryptococcal meningitis,which can effectively reduce the microbial content of cerebrospinal fluid cryptococcus. But more monitoring on incidence of adverse reactions is needed to ensure its rationality and safety.
出处 《中国现代医生》 2016年第21期111-113,共3页 China Modern Doctor
关键词 氟康唑 隐球菌脑膜炎 两性酶素B 脑脊液隐球菌菌数 Fluconazole Cryptococcal meningitis Amphotericin B Microbial content of cerebrospinal fluid cryptococcus
  • 相关文献

参考文献15

二级参考文献34

  • 1郭爱华,胡学强.新型隐球菌颅内感染101例临床特点及诊断[J].中华神经科杂志,2005,38(7):445-447. 被引量:22
  • 2翁心华,朱利平.重视隐球菌脑膜炎的治疗[J].中华传染病杂志,2007,25(4):193-194. 被引量:18
  • 3陈明泉,施光峰,秦刚,李谦,张琼华,张玉杰,翁心华.隐球菌脑膜炎146例临床分析[J].中华传染病杂志,2007,25(4):199-202. 被引量:23
  • 4Segal BH,Herbrecht R,Stevens DA,et al.Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases:Mycoses Study Group and European Organization for Re.arch and Treatment of Cancer consensus criteria.Clin Infect Dis,2008,47:674-683.
  • 5Jarvis JN,Harrison TS.HIV-associated cryptococeal meningitis.AIDS,2007,21:2119-2129.
  • 6Mirza SA,Phelan M,Rimland D,et al.The changing epidemiology of cryptococcosis:an update from populationbased active surveillance in 2 large metropolitan areas,1992-2000.Clin Infect Dis,2003,36:789-794.
  • 7Dromer F,Mathoulin-Pélissier S,Fontanet A,et al.Epidemiology of HIV-associated cryptococcosis in France (1985-2001):comparison of the pre-and post-HAART eras.AIDS,2004,18:555-562.
  • 8Kiertiburanakul S,Wirojtananugoon S,Pracharktam R,et al.Cryptocoecosis in human immunodeficiency virusnegative patients.Int J Infect Dis,2008,10:72-78.
  • 9Lui G,Lee N,Ip M,et al.Cryptocoecosis in apparently immunocompetent patients.QJM,2006,99:143-151.
  • 10Singh N,Dromer F,Perfect JR,et al.Cryptococcosis in solid organ transplant recipients,current state of the science.Clin Infect Dis,2008,47:1321-1327.

共引文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部